Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Differences in efficacy between formoterol and salmeterol in relaxation of the mouse trachea are accentuated by inflammatory cytokines Source: Eur Respir J 2005; 26: Suppl. 49, 370s Year: 2005
Lack of glucocorticoid receptor activation by formoterol and salmeterol in human bronchial epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 454s Year: 2003
Formoterol but not salmeterol enhances cytokine release Source: Eur Respir J 2002; 20: Suppl. 38, 619s Year: 2002
Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Rapid inhibitory effects of budesonide and formoterol on bradykinin-induced Ca2+ mobilization in human lung fibroblasts Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Combination of budesonide and formoterol is more effective in inhibiting GM-CSF production by bronchial epithelial cells than either drug alone Source: Eur Respir J 2003; 22: Suppl. 45, 457s Year: 2003
Effects of fluticasone and salmeterol on cytokine-induced airway smooth muscle IP10 release Source: Eur Respir J 2005; 26: Suppl. 49, 712s Year: 2005
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
Effect of fluticasone and formoterol combination therapy on airway remodeling Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Source: Eur Respir J 2002; 19: 865-871 Year: 2002
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC) Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Formoterol is more effective than salmeterol in suppressing neutrophil reactivity Source: ERJ Open Res 2015 Year: 2015
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006